Chiesi and UCB enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases
30 Novembre 2021
Chiesi Research Centre: 10 years’ scientific innovation serving the community
18 Ottobre 2021
Chiesi receives positive ESG rating from independent rating agency Cerved
23 Settembre 2021
CLIMATE CHANGE – A MAJOR THREAT TO RESPIRATORY HEALTH IN EUROPE SAYS NEW REPORT FROM ECONOMIST INTELLIGENCE UNIT
07 Settembre 2021
ERS Congress 2021 – Important updates on Asthma and COPD treatments presented at the Symposium organised by Chiesi “Unlock Every Breath: finding the right key to improve Respiratory Therapy”
06 Settembre 2021
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
23 Giugno 2021
Chiesi Group calls for #ActionOverWords in the fight against climate change
10 Maggio 2021
New organisational order for the Chiesi Foundation
03 Maggio 2021
Chiesi Group receives European Marketing Authorisation for its triple combination therapy inhalation powder (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) in extrafine fixed formulation delivered through NEXThaler, for the treatment of moderate to severe COPD
21 Aprile 2021
Chiesi continues cultural transformation with new visual identity that mirrors patients’ language and experiences
